Plus: Nouscom raises €67.5M series C and more from Eyebio, Glox, Bayer and Ketabon

Plus FDA panel declines to back Copiktra and updates from AstraZeneca, Ionis and more

Plus Celltrion gains rights to T cell engager from Abpro, and updates from Moat, Day One, Secura and more

Three cancer therapies on the agenda, plus an ALS therapy and a live fecal microbiota

FDA says Pepaxto, Copiktra may cause higher risk of death, but EMA has recently endorsed both

FDA advisory committee votes down single-arm studies for PI3K inhibitor approval

FDA’s ODAC to discuss the regulatory pathway for PI3K inhibitors this week

Plus new CTO, CDO at Finch; and updates from Generation Bio, Atea and more

GSK’s Benlysta and J&J’s Ponvory are two of the latest therapies to win support from EMA’s CHMP, which did not issue any negative recommendations in March. The